Insulet (NASDAQ:PODD) Reaches New 12-Month Low – Here’s Why

Insulet Corporation (NASDAQ:PODD)’s stock price reached a new 52-week low during mid-day trading on Monday . The company traded as low as $139.23 and last traded at $139.9680, with a volume of 159812 shares changing hands. The stock had previously closed at $145.76.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Robert W. Baird dropped their target price on Insulet from $360.00 to $248.00 in a research report on Thursday, May 7th. Jefferies Financial Group lowered their price target on shares of Insulet from $400.00 to $360.00 in a research report on Thursday, May 7th. Benchmark reaffirmed a “buy” rating on shares of Insulet in a report on Wednesday, May 27th. Truist Financial cut their price objective on shares of Insulet from $250.00 to $219.00 and set a “buy” rating on the stock in a research report on Thursday, June 11th. Finally, Rothschild & Co Redburn reissued a “neutral” rating and set a $220.00 target price (down from $380.00) on shares of Insulet in a research note on Friday, April 24th. Twenty-one research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Insulet presently has a consensus rating of “Moderate Buy” and a consensus price target of $240.78.

Insulet Stock Down 4.1%

The company has a market cap of $9.68 billion, a price-to-earnings ratio of 32.53, a price-to-earnings-growth ratio of 1.15 and a beta of 1.13. The stock has a 50-day simple moving average of $164.18 and a 200-day simple moving average of $225.67. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The company had revenue of $761.70 million for the quarter, compared to analyst estimates of $729.89 million. During the same period last year, the company earned $1.02 earnings per share. The company’s quarterly revenue was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, analysts predict that Insulet Corporation will post 6.46 EPS for the current year.

Insider Buying and Selling

In related news, Director Timothy C. Stonesifer bought 2,790 shares of the stock in a transaction on Wednesday, June 3rd. The shares were purchased at an average price of $143.51 per share, with a total value of $400,392.90. Following the purchase, the director owned 9,041 shares in the company, valued at approximately $1,297,473.91. This represents a 44.63% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.36% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Larson Financial Group LLC increased its stake in shares of Insulet by 114.6% during the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 47 shares during the period. University of Texas Texas AM Investment Management Co. acquired a new stake in Insulet in the fourth quarter worth approximately $26,000. DV Equities LLC acquired a new stake in Insulet in the fourth quarter worth approximately $28,000. Elyxium Wealth LLC bought a new position in Insulet during the 4th quarter valued at $28,000. Finally, Mcguire Capital Advisors Inc. bought a new position in Insulet during the 4th quarter valued at $29,000.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.